Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.

K, Ogino; M, Kato; Y, Furuse; Y, Kinugasa; K, Ishida; S, Osaki; T, Kinugawa; O, Igawa; I, Hisatome; C, Shigemasa; SD, Anker; W, Doehner

doi:10.1161/circheartfailure.109.868604

Public

Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.

Shared by NobleBlocks on Nov 20, 2009 • 12:00 AM UTC

Authors:

Ogino K

Kato M

Furuse Y

Abstract

<h4>Background</h4>Hyperuricemia is common in chronic heart failure (CHF), and it is a strong independent marker of prognosis. Upregulated xanthine oxidase (XO) activity and impaired renal excretion have been shown to account for increased serum uric acid (UA) levels in CHF. Therapeutic intervention...

Discussions